not entirely unreasonable. This is why the Novartis agreement is now so significant, as without that or other significant partnership income then we’ll certainly be facing a CR in the first half of 2022. Unless there is a significant catalyst to drive the price up, it would be at these low levels which means significant dilution.
The market seemingly being at the top doesn’t help either as that’s just going to add further downward pressure. It’s so grim as a long right now. We just have to pray for some great news.
This weeks reporting dragging into tomorrow feels like further bad news (or no news) as well.
just a few more weeks hey…
not entirely unreasonable. This is why the Novartis agreement is...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.09 |
Change
0.015(1.40%) |
Mkt cap ! $1.238B | |||
| Open | High | Low | Value | Volume |
| $1.11 | $1.12 | $1.08 | $11.51M | 10.52M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 17804 | $1.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.09 | 230637 | 5 |
View Market Depth
| Last trade - 16.10pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.09 |
Change
0.015 ( 1.85 %) |
||||
| Open | High | Low | Volume | ||
| $1.10 | $1.12 | $1.08 | 1937390 | ||
| Last updated 15.59pm 03/05/2024 ? | |||||
| MSB (ASX) Chart |